Regev-Yochay Gili, Jaber Hanaa, Hamdan Ayob, Daana Muhannad, Nammouz Hanan, Thalji Amin, Jaar Fuad, Abdeen Ziad, Rubin Carmit, Huppert Amit, Raz Meir, Rahav Galia
Infectious Dis. Unit, Sheba Med Ctr, Ramat-Gan, Israel; Section of Infectious Dis. Epidemiology, Gertner Institute for Epidemiology Research, Ramat-Gan, Israel.
Infectious Dis. Unit, Sheba Med Ctr, Ramat-Gan, Israel.
Vaccine. 2016 May 27;34(25):2787-92. doi: 10.1016/j.vaccine.2016.04.064. Epub 2016 Apr 29.
Type1-pilus proteins were suggested as targets of future protein-based vaccines. Here we studied the effect of pneumococcal-conjugate vaccine (PCV7) implementation on the prevalence of piliated strains in a unique study setting which controls for typical confounders; the Palestinian-Israeli Collaborative Research (PICR).
Annual cross-sectional surveys of pneumococcal carriage were performed during 2009-2011 among two closely related population that live under different health policies (a) Palestinian-Authority (PA) (n=1773), where PCV7 was not yet introduced (b) East-Jerusalem (EJ) (n=983) where PCV7 was rapidly implemented. Clinical data were collected, pneumococci identified and characterized and the presence of Type1-pilus genes was determined by rrgC PCR.
Following PCV7 implementation in EJ, overall carriage prevalence did not change (∼30%), but VT7 strains decreased from 61.5% to 33.8%. While prevalence of non-piliated-VT7 isolates decreased from 37% to 10%, p<0.001, the prevalence of piliated-VT7 strains persisted ∼25%. Additionally, piliated non-VT13 strains emerged (1-15%, p<0.001). These changes were not observed in PA. These dynamics were independent of the bacteria's resistance pattern.
A differential effect of PCV7 was observed with a relative resistance of piliated strains to the vaccine. This suggests that Type1-pilus confers an intrinsic advantage for colonization and may be an attractive vaccine target.
1型菌毛蛋白被认为是未来基于蛋白质的疫苗的靶点。在此,我们在一个独特的研究环境中,即巴勒斯坦-以色列合作研究(PICR)中,研究了肺炎球菌结合疫苗(PCV7)的实施对菌毛菌株流行率的影响,该研究控制了典型的混杂因素。
在2009年至2011年期间,对生活在不同卫生政策下的两个密切相关人群进行了肺炎球菌携带情况的年度横断面调查:(a)巴勒斯坦权力机构(PA)(n = 1773),尚未引入PCV7;(b)东耶路撒冷(EJ)(n = 983),PCV7已迅速实施。收集临床数据,鉴定和表征肺炎球菌,并通过rrgC PCR确定1型菌毛基因的存在。
在EJ实施PCV7后,总体携带率没有变化(约30%),但VT7菌株从61.5%降至33.8%。非菌毛VT7分离株的流行率从37%降至10%,p<0.001,菌毛VT7菌株的流行率持续在25%左右。此外,出现了菌毛非VT13菌株(1%-15%,p<0.001)。在PA中未观察到这些变化。这些动态与细菌的耐药模式无关。
观察到PCV7有不同的效果,菌毛菌株对该疫苗具有相对抗性。这表明1型菌毛赋予了定植的内在优势,可能是一个有吸引力的疫苗靶点。